The primary therapeutic role of Проспан is to provide targeted symptomatic support for respiratory issues involving mucus accumulation. It is commonly used across patient groups experiencing acute or episodic changes where short-term symptomatic assistance is generally needed.

Ivy leaf preparations are considered relevant for easing symptoms related to the presence of mucus. The medication is relevant for conditions characterized by periods of heightened symptoms such as acute catarrh of the respiratory tract and minor bronchial irritation.

Relief for Productive (Chesty) Cough

The medication is used to address a key symptom: the productive cough that occurs when thick, sticky mucus or phlegm is present in the airways. This is applied when symptoms create noticeable physiological strain, and additional symptomatic support is needed to help the body clear these secretions. The therapeutic focus is relevant for easing the symptoms related to secretion retention and supporting a more manageable cough, which may help patients cope more steadily with difficult episodes.

“The supportive relief of symptoms like congestion and difficult expectoration contributes to easing the overall symptom load during periods of temporary physiological imbalance.”

Support for Acute Airway Congestion

Проспан is relevant in clinical settings that involve conditions presenting with systemic or localized discomfort, such as acute respiratory congestion. It is commonly used to help with groups of symptoms, including congestion and difficult expectoration, which cluster into patterns that interfere with daily comfort. This supportive relief contributes to easing the overall symptom load during symptomatic periods and may assist with managing acute or disruptive episodes.

Quick Fact: Relief for Mucus-Related Cough The medication is considered relevant for easing the symptoms of productive cough and difficult expectoration associated with acute conditions of the respiratory tract.

Regulatory References

1. European Medicines Agency (EMA) overview on Ivy leaf

Eligibility Map: Who Can and Cannot Use Проспан — Official Regulatory Information

Official regulatory documents define the eligibility for Prospan based on age, physiological state, and known hypersensitivities. The following statements summarize who is prohibited or restricted from using the medicine.

Eligibility Classification	Details (As Per Official Labeling)
Absolute Contraindications	Hypersensitivity (allergy) to ivy leaf extract (the active ingredient), or to any other component (excipients) in the medicine.
Age-Related Restrictions	Contraindicated: Use in children under 2 years of age is generally prohibited in regulatory labels due to the risk of worsening respiratory symptoms. Recommended Use: Generally approved for adults, adolescents, and children from 2 years of age, though specific minimum ages (e.g., 6 or 12) may apply for certain formulations or jurisdictions.
Physiological Restrictions	Not Recommended: Use during pregnancy and breastfeeding is officially not recommended due to the lack of sufficient safety data established by clinical trials.
Conditional Use/Caution	Individuals with conditions like gastritis or gastric ulcer must seek consultation from a healthcare professional before use. Similarly, caution is required for individuals with an intolerance to certain sugars, such as sorbitol, which is present in some forms of the medicine.

Interactions with other medicines and products

The official regulatory profile for Проспан (Hederae Helicis Foliorum Extract) is established by the specific caution against co-administration with certain cough-suppressing medicines and the explicit absence of clinical pharmacokinetic interaction data.

Pharmacodynamic Co-administration Restriction

A specific caution applies to opiate antitussives, including medicinal products such as Codeine and Dextromethorphan. These combinations are subject to an explicit regulatory restriction: concomitant use with such antitussive products is not recommended without consulting a health professional. This is classified as a pharmacodynamic restriction, which formally addresses the potential for the expectorant effect of the extract to be counteracted by the cough-suppressant properties of the co-administered antitussive. This is the only substance category identified with a specific co-administration constraint in the regulatory labels.

Absence of Documented Pharmacokinetic Profile

Regulatory assessments explicitly state that no formal interaction studies have been performed to evaluate the product's potential effects on metabolic enzymes, such as the cytochrome P450 (CYP) systems, or drug transporters. Consequently, the official labeling contains no documented pharmacokinetic interactions, meaning no substances are officially listed as clinically modifying the exposure (AUC or Cmax) of the extract. Furthermore, the regulatory documents contain no explicit rules concerning mandatory dose timing separation, population-specific interaction notes, or documented interactions with food, alcohol, or other herbal products.

Modulation of beta2-Adrenergic Receptor Function

The molecular process begins with the active component, alpha-hederin, which acts as an indirect inhibitor of the enzyme GRK2 (G protein-coupled receptor kinase 2). This critical interaction prevents the desensitization of the mathbfbeta2-adrenergic receptors (beta2 AR) found on the surface of lung cells, thereby stabilizing and modifying the receptor's responsiveness to endogenous signals.

---

Dual Physiological Cascade (Spasmolysis and Secretolysis)

This sustained beta2 AR signaling initiates a coordinated dual physiological cascade via the cAMP pathway. In bronchial smooth muscle cells, the cascade promotes relaxation, resulting in smooth muscle relaxation and promoting bronchospasmolysis. Simultaneously, the signaling stimulates alveolar type II cells to increase the release of pulmonary surfactant and fluid. This action reduces the viscosity of secretions, modulating the natural ciliary clearance mechanisms of the airways.

Administration Guidelines for Проспан

Administration Scope

The route of administration for all Проспан formulations, including syrup, drops, and tablets, is oral use. The dosing schedule is defined by age, with the regimen typically requiring the dose to be divided and taken three times daily.

Feature	Instruction Summary
Adult and Adolescent Dosing	5 to 7.5 mL (syrup) per dose, three times daily, for individuals 12 years and over.
Pediatric Dosing	Children aged 6 to 11 years are instructed to take 5 mL three times daily, while children aged 2 to 5 years are administered 2.5 mL three times daily.
Timing in relation to meals	The administration is typically taken regardless of meals.

Preparation and Procedural Steps

Specific procedural steps are followed for administration. Liquid forms must be shaken well before use, and a measuring device is used to ensure accurate volumetric dosing. In the event of a missed scheduled dose, a double dose should not be taken; instead, the next regularly scheduled dose is continued.

Treatment duration is time-bound. Instructions state that administration should continue for a minimum of one week and for 2 to 3 days after the symptoms have subsided, following the defined age-specific frequency pattern.

Research Evidence / Overview of Studies for Проспан

Evidence for Use in Acute Cough and Acute Bronchitis

Research explored the specific ivy leaf extract (EA 575) in studies evaluating patient-reported outcomes related to acute cough linked to acute respiratory tract infections (ARTI) and acute bronchitis. The core body of evidence includes short-term Randomized Controlled Trials (RCTs), where the extract was evaluated in research settings against a placebo or an active comparator. These studies focused on measuring outcomes describing episodic or acute changes in adult and pediatric populations.

Research has explored various ways to measure how symptoms evolved in the studied populations. Trials monitored patient-reported outcomes such as changes in the Bronchitis Severity Score (BSS), which evaluates symptom clusters. The findings describe patterns observed in the studies over the short-term follow-up periods, typically lasting around one week to ten days, which contributes to the broader evidence landscape.

Evidence in Special Populations

Research was evaluated in various age groups, meaning the results apply only to the populations studied. Clinical trials and observational studies explored this extract in both adults and pediatric patients, including infants and school-aged children who presented with acute respiratory symptoms.

Studies explored patient-reported outcomes describing perceived discomfort in a younger population. Systematic reviews have noted that some pediatric studies included sample sizes were modest, and the evidence quality varies across studies due to differences in design. Research was studied for acute, uncomplicated cough. Data for certain groups remain insufficient, such as patients with significant underlying chronic lung conditions.

Evidence Quality and Key Research Limitations

The scientific evaluation includes evidence from RCTs and numerous large-scale post-marketing studies. However, the evidence quality varies across studies, as systematic reviews sometimes note methodological heterogeneity in trial designs. A primary limitation is the reliance on subjective outcome measures; many key findings depend on patient-reported severity scores, which contributes to understanding symptom patterns. Comparative evidence is lacking against a full range of alternative or standard therapies. Study results reflect the specific conditions under which they were conducted and do not provide individual predictions.

Key Studies & References

1. Efficacy and tolerability of a standardised extract from ivy leaves in patients with acute bronchitis: a multicentre, open, randomized clinical trial versus an expectorant

Common questions about Проспан (FAQ)

Q: What is the main difference between Проспан and a simple cough suppressant?

A: Проспан is classified in official documents as a traditional herbal medicinal product used to relieve chesty coughs. Its function is primarily that of an expectorant, which means its established activity is to support the loosening and thinning of mucus, thereby facilitating airway clearance. This action is distinct from a simple cough suppressant, which acts centrally to restrict the cough reflex itself.

---

Q: Is it common to use Проспан for a cough lasting several weeks?

A: Official guidance indicates that treatment should continue for at least one week and for two to three days after the symptoms of the cough have subsided. However, regulatory warnings state that if symptoms persist for longer than one week, or if they worsen, it is recommended to seek advice from a doctor or pharmacist for further evaluation.

---

Q: Is there a version of Проспан that is alcohol-free?

A: The active ingredient's extract is often prepared using an alcohol solvent. However, some specific finished product labels state that the formulation is 'alcohol-free.' Patients are directed to review the official labeling of their specific version for the exact component list.

---

Q: Does Проспан contain sugar or any artificial sweeteners?

A: The official product labeling indicates that the medicine often contains the sugar substitute sorbitol as an excipient (inactive ingredient). The precise quantity of sorbitol is specified on the official label. Individuals with known intolerances to certain sugars may consider consulting a healthcare professional prior to use.

---

Q: Is Проспан considered safe to use during pregnancy?

A: Official product information states that safety has not been established during pregnancy and lactation due to the lack of sufficient regulatory data. Because of this official lack of data, its use during these periods is a regulatory caution.

---

Q: Can Проспан affect my ability to drive or operate machinery?

A: Official documents note that no specific studies have been performed to evaluate the product’s effect on the ability to drive or use machines. Based on the documented side effects, official labeling typically lists no known effects on these abilities.

---

Q: Why is Проспан not recommended for children under a certain age?

A: Official product documentation explicitly contraindicates (forbids) the use of this product in children under 2 years of age. This restriction is based on the documented risk of certain adverse events, such as worsening respiratory symptoms (dyspnoea), in this age group.

---

Q: Is Проспан known to interact with common pain relievers like ibuprofen?

A: The official product information states that no formal interaction studies have been conducted to evaluate the effects of the extract on the metabolism of other medicines. The only specific co-administration constraint listed in regulatory documents is related to certain opiate antitussives (cough suppressants).

---

Q: Can Проспан be taken by people with a sensitive stomach or history of gastritis?

A: Official warnings recommend that caution is used when taking this product if a patient has a history of gastritis (stomach inflammation) or a gastric ulcer. This caution is given because the most commonly reported side effects relate to the gastrointestinal system.

---

Q: How is the extract in Проспан prepared or standardized?

A: The active substance is prepared as a dry extract of Ivy leaf, and official labeling specifies details about its preparation. This includes the Drug-to-Extract Ratio (DER) and the specific extraction solvent used, which is typically a percentage of ethanol.

---

Q: If my cough doesn't improve after a week of using Проспан, what does the official guidance recommend?

A: Official guidance states that if the symptoms of the cough worsen or persist for longer than one week of use, the user should refer to a doctor or qualified healthcare practitioner for further evaluation.

---

Q: Are there any specific excipients (inactive ingredients) in Проспан that cause common side effects?

A: Official labeling lists sorbitol as an excipient. Warnings are included stating that products containing sorbitol may, in some patients, cause a laxative effect or lead to diarrhoea.

---

Q: Can I take Проспан if I am breastfeeding?

A: Similar to pregnancy, official regulatory safety has not been established for use during lactation due to a lack of sufficient data. Therefore, the use of this medicine while breastfeeding is a regulatory caution.

---

Q: Does Проспан relieve cough symptoms by relaxing the airways?

A: The mechanism of action is described in official documents as promoting bronchospasmolysis. This refers to the relaxation of the smooth muscles in the airways, which may support the overall relief of cough symptoms.

---

Q: Is Проспан suitable for use by the elderly?

A: The official dosing table includes the dosage for Adults, the elderly, and children aged 12 years and over as one combined population. This indicates that the medicine is included in the recommended usage population for elderly individuals.

---

Q: Are there reports of paradoxical coughing (cough worsening) after taking Проспан?

A: Official documents list shortness of breath (dyspnoea) as a possible serious allergic reaction. Additionally, the restriction for children under 2 years of age is specifically related to the risk of worsening respiratory symptoms.

---

Q: How can I tell the difference between a mild side effect and an allergic reaction to Проспан?

A: Official documents categorize side effects into two main types: generally uncommon Gastrointestinal issues (like nausea or diarrhoea) and less frequent Allergic reactions (like skin rash, or shortness of breath). Allergic reactions are listed as possible serious outcomes, and the regulatory guidance suggests seeking medical attention if symptoms of a serious allergic reaction, such as shortness of breath, occur.

---

Q: Can Проспан be used alongside antibiotics for a respiratory infection?

A: Official information specifies a restriction only for certain opiate antitussives (cough suppressants). The documentation contains no specific warnings or restrictions regarding co-administration with antibiotics. However, it is noted that no formal interaction studies are cited for any substance other than the opiate antitussives.

---

Q: Are there different formulations of Проспан (e.g., syrup, drops, tablets)?

A: The active substance is made available in several officially registered pharmaceutical forms to suit different patient needs. These forms commonly include liquid options like syrup and drops, as well as solid forms such as tablets.

---

Q: What is the meaning of 'traditional herbal medicinal product' as it applies to Проспан?

A: This is a regulatory classification indicating that the product's effectiveness is based on its traditional use only for a specified indication, such as cough relief. This designation is based on the long established use of the product's ingredients over time.

---

Q: What does it mean that Проспан is 'alcohol-free' if some versions contain ethanol?

A: Official product information must declare the content of ethanol if it is present in the final product. If a specific version is officially labeled as 'alcohol-free,' it means that version does not contain the alcohol used in the extraction process or any added alcohol.

---

Q: How is the dose for Проспан determined in clinical use?

A: The official administration schedule is determined strictly by the patient's age group, according to regulatory guidelines. Age dictates both the specific volume (e.g., milliliters) and the frequency (e.g., three times daily) of administration.

---

Q: Is it true that Проспан has been used for hundreds of years in traditional medicine?

A: The product is officially classified by regulatory bodies as a traditional herbal medicinal product. This classification itself is a designation based on its established long history of use for the specified indication.

How to Store and Dispose of Проспан?

Official regulatory documents define mandatory requirements for storing and disposing of Проспан to maintain its stability and ensure environmental safety.

Storage Conditions

Проспан (syrup, solution, and tablets) must be stored at a temperature below 25°C and should be kept in the original container to protect it from light. A critical safety requirement is to keep the medicine out of the sight and reach of children.

Stability Constraint	Requirement (Liquid Formulations)
Overall Shelf-Life	Do not use after the stated expiry date.
In-Use Stability	Discard after 3 months of first opening the bottle.

Disposal Instructions

To prevent environmental contamination, official labeling states that Проспан should not be thrown away with household waste or flushed down wastewater. Users are required to ask a pharmacist for the correct procedure on how to safely dispose of unused or expired medicine.